IL89701A - Recombinant retroviruses method for the production thereof and pharmaceutical compositions containing the same - Google Patents

Recombinant retroviruses method for the production thereof and pharmaceutical compositions containing the same

Info

Publication number: IL89701A
Authority: IL; Israel
Prior art keywords: cells; expression; recombinant retrovirus; retrovirus; vector
Prior art date: 1988-03-21

Application number

IL8970189A

Other languages

English (en)

Other versions

IL89701A0 (en

Original Assignee

Viagene Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-03-21

Filing date

1989-03-21

Publication date

1995-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22620165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL89701(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1989-03-21 Application filed by Viagene Inc filed Critical Viagene Inc

1989-09-28 Publication of IL89701A0 publication Critical patent/IL89701A0/xx

1995-07-31 Publication of IL89701A publication Critical patent/IL89701A/en

Links

241001430294 unidentified retrovirus Species 0.000 title claims abstract description 111
238000000034 method Methods 0.000 title claims abstract description 81
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
238000004519 manufacturing process Methods 0.000 title claims description 31
239000013598 vector Substances 0.000 claims abstract description 216
238000004806 packaging method and process Methods 0.000 claims abstract description 82
241000700605 Viruses Species 0.000 claims abstract description 55
230000001717 pathogenic effect Effects 0.000 claims abstract description 55
241001465754 Metazoa Species 0.000 claims abstract description 48
239000003795 chemical substances by application Substances 0.000 claims abstract description 47
208000015181 infectious disease Diseases 0.000 claims abstract description 41
239000000427 antigen Substances 0.000 claims abstract description 32
108091007433 antigens Proteins 0.000 claims abstract description 32
102000036639 antigens Human genes 0.000 claims abstract description 32
230000028993 immune response Effects 0.000 claims abstract description 20
230000002401 inhibitory effect Effects 0.000 claims abstract description 17
230000002458 infectious effect Effects 0.000 claims abstract description 16
230000003993 interaction Effects 0.000 claims abstract description 14
230000004936 stimulating effect Effects 0.000 claims abstract description 5
210000004027 cell Anatomy 0.000 claims description 318
108090000623 proteins and genes Proteins 0.000 claims description 198
230000014509 gene expression Effects 0.000 claims description 91
102000004169 proteins and genes Human genes 0.000 claims description 89
230000003612 virological effect Effects 0.000 claims description 62
239000002245 particle Substances 0.000 claims description 29
230000010076 replication Effects 0.000 claims description 24
210000001744 T-lymphocyte Anatomy 0.000 claims description 23
230000002950 deficient Effects 0.000 claims description 23
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 22
206010028980 Neoplasm Diseases 0.000 claims description 17
230000010354 integration Effects 0.000 claims description 17
230000027455 binding Effects 0.000 claims description 16
230000000903 blocking effect Effects 0.000 claims description 16
230000000694 effects Effects 0.000 claims description 15
101710091045 Envelope protein Proteins 0.000 claims description 14
101710188315 Protein X Proteins 0.000 claims description 14
230000004044 response Effects 0.000 claims description 12
230000006798 recombination Effects 0.000 claims description 11
231100000331 toxic Toxicity 0.000 claims description 11
230000002588 toxic effect Effects 0.000 claims description 11
108090000765 processed proteins & peptides Proteins 0.000 claims description 10
238000005215 recombination Methods 0.000 claims description 10
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 claims description 9
239000003184 complementary RNA Substances 0.000 claims description 8
230000004048 modification Effects 0.000 claims description 8
238000012986 modification Methods 0.000 claims description 8
244000052769 pathogen Species 0.000 claims description 8
108020005544 Antisense RNA Proteins 0.000 claims description 7
108091005804 Peptidases Proteins 0.000 claims description 7
239000004365 Protease Substances 0.000 claims description 7
108020004440 Thymidine kinase Proteins 0.000 claims description 6
201000011510 cancer Diseases 0.000 claims description 5
230000001225 therapeutic effect Effects 0.000 claims description 5
238000002560 therapeutic procedure Methods 0.000 claims description 5
102000006601 Thymidine Kinase Human genes 0.000 claims description 4
210000000234 capsid Anatomy 0.000 claims description 4
101710172711 Structural protein Proteins 0.000 claims description 3
230000009102 absorption Effects 0.000 claims description 3
238000010521 absorption reaction Methods 0.000 claims description 3
230000000295 complement effect Effects 0.000 claims description 3
210000000987 immune system Anatomy 0.000 claims description 3
230000007918 pathogenicity Effects 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
241000700584 Simplexvirus Species 0.000 claims description 2
108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 2
102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 2
150000001875 compounds Chemical class 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
231100001083 no cytotoxicity Toxicity 0.000 claims description 2
238000012545 processing Methods 0.000 claims description 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
108060003951 Immunoglobulin Proteins 0.000 claims 1
239000003102 growth factor Substances 0.000 claims 1
102000018358 immunoglobulin Human genes 0.000 claims 1
230000006916 protein interaction Effects 0.000 claims 1
230000009261 transgenic effect Effects 0.000 abstract description 19
208000023275 Autoimmune disease Diseases 0.000 abstract description 4
241000238631 Hexapoda Species 0.000 abstract description 3
230000003405 preventing effect Effects 0.000 abstract 1
230000000087 stabilizing effect Effects 0.000 abstract 1
230000001177 retroviral effect Effects 0.000 description 88
239000012634 fragment Substances 0.000 description 59
239000013612 plasmid Substances 0.000 description 42
210000001519 tissue Anatomy 0.000 description 32
108020004414 DNA Proteins 0.000 description 23
101710149951 Protein Tat Proteins 0.000 description 23
239000000047 product Substances 0.000 description 23
239000013603 viral vector Substances 0.000 description 23
238000000338 in vitro Methods 0.000 description 20
238000010276 construction Methods 0.000 description 19
230000006870 function Effects 0.000 description 19
238000011282 treatment Methods 0.000 description 19
230000001566 pro-viral effect Effects 0.000 description 17
241000714177 Murine leukemia virus Species 0.000 description 16
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 15
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 14
102100034343 Integrase Human genes 0.000 description 14
102100034349 Integrase Human genes 0.000 description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
239000003814 drug Substances 0.000 description 14
239000003550 marker Substances 0.000 description 14
208000031886 HIV Infections Diseases 0.000 description 13
241000699670 Mus sp. Species 0.000 description 13
229960004150 aciclovir Drugs 0.000 description 13
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 13
201000010099 disease Diseases 0.000 description 13
229940079593 drug Drugs 0.000 description 13
108010078428 env Gene Products Proteins 0.000 description 13
241000701161 unidentified adenovirus Species 0.000 description 13
241000894006 Bacteria Species 0.000 description 12
102100034353 Integrase Human genes 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
208000037357 HIV infectious disease Diseases 0.000 description 11
102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 11
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 11
108010027225 gag-pol Fusion Proteins Proteins 0.000 description 11
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 11
108020004774 Alkaline Phosphatase Proteins 0.000 description 10
108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 10
108010061833 Integrases Proteins 0.000 description 10
230000000692 anti-sense effect Effects 0.000 description 10
238000013459 approach Methods 0.000 description 10
238000003780 insertion Methods 0.000 description 10
230000037431 insertion Effects 0.000 description 10
108091008146 restriction endonucleases Proteins 0.000 description 10
238000009585 enzyme analysis Methods 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
239000002773 nucleotide Substances 0.000 description 9
102000002260 Alkaline Phosphatase Human genes 0.000 description 8
108010067390 Viral Proteins Proteins 0.000 description 8
230000001086 cytosolic effect Effects 0.000 description 8
229940127089 cytotoxic agent Drugs 0.000 description 8
239000002254 cytotoxic agent Substances 0.000 description 8
108700004025 env Genes Proteins 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
230000008685 targeting Effects 0.000 description 8
230000002103 transcriptional effect Effects 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 7
238000003556 assay Methods 0.000 description 7
230000001413 cellular effect Effects 0.000 description 7
231100000433 cytotoxic Toxicity 0.000 description 7
230000001472 cytotoxic effect Effects 0.000 description 7
239000002502 liposome Substances 0.000 description 7
108010089520 pol Gene Products Proteins 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
230000014616 translation Effects 0.000 description 7
108091026890 Coding region Proteins 0.000 description 6
239000012636 effector Substances 0.000 description 6
101150030339 env gene Proteins 0.000 description 6
239000000284 extract Substances 0.000 description 6
230000003308 immunostimulating effect Effects 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
230000002147 killing effect Effects 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
210000001616 monocyte Anatomy 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
238000001890 transfection Methods 0.000 description 6
238000013519 translation Methods 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
241000450599 DNA viruses Species 0.000 description 5
102000003676 Glucocorticoid Receptors Human genes 0.000 description 5
108090000079 Glucocorticoid Receptors Proteins 0.000 description 5
208000026350 Inborn Genetic disease Diseases 0.000 description 5
108020004511 Recombinant DNA Proteins 0.000 description 5
108700008625 Reporter Genes Proteins 0.000 description 5
230000008901 benefit Effects 0.000 description 5
230000006378 damage Effects 0.000 description 5
238000012217 deletion Methods 0.000 description 5
230000037430 deletion Effects 0.000 description 5
208000016361 genetic disease Diseases 0.000 description 5
238000002744 homologous recombination Methods 0.000 description 5
230000006801 homologous recombination Effects 0.000 description 5
229960001438 immunostimulant agent Drugs 0.000 description 5
239000003022 immunostimulating agent Substances 0.000 description 5
231100000518 lethal Toxicity 0.000 description 5
230000001665 lethal effect Effects 0.000 description 5
125000003729 nucleotide group Chemical group 0.000 description 5
230000008569 process Effects 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
108010041397 CD4 Antigens Proteins 0.000 description 4
108700005090 Lethal Genes Proteins 0.000 description 4
108060001084 Luciferase Proteins 0.000 description 4
101710150344 Protein Rev Proteins 0.000 description 4
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
241000700618 Vaccinia virus Species 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000037396 body weight Effects 0.000 description 4
210000001185 bone marrow Anatomy 0.000 description 4
231100000599 cytotoxic agent Toxicity 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
239000000203 mixture Substances 0.000 description 4
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
239000002243 precursor Substances 0.000 description 4
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 4
230000003362 replicative effect Effects 0.000 description 4
241000894007 species Species 0.000 description 4
210000000130 stem cell Anatomy 0.000 description 4
238000003860 storage Methods 0.000 description 4
239000000758 substrate Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
210000002845 virion Anatomy 0.000 description 4
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
208000030507 AIDS Diseases 0.000 description 3
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 3
230000004568 DNA-binding Effects 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
101710177291 Gag polyprotein Proteins 0.000 description 3
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
108091006905 Human Serum Albumin Proteins 0.000 description 3
102000008100 Human Serum Albumin Human genes 0.000 description 3
239000005089 Luciferase Substances 0.000 description 3
102000043129 MHC class I family Human genes 0.000 description 3
108091054437 MHC class I family Proteins 0.000 description 3
101710125418 Major capsid protein Proteins 0.000 description 3
102000018697 Membrane Proteins Human genes 0.000 description 3
108010052285 Membrane Proteins Proteins 0.000 description 3
241001529936 Murinae Species 0.000 description 3
108700020796 Oncogene Proteins 0.000 description 3
241000714474 Rous sarcoma virus Species 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
108020004566 Transfer RNA Proteins 0.000 description 3
206010046865 Vaccinia virus infection Diseases 0.000 description 3
108700005077 Viral Genes Proteins 0.000 description 3
108020000999 Viral RNA Proteins 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
230000000840 anti-viral effect Effects 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
239000002981 blocking agent Substances 0.000 description 3
210000000349 chromosome Anatomy 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
108010038795 estrogen receptors Proteins 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
239000002609 medium Substances 0.000 description 3
230000035772 mutation Effects 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
230000008506 pathogenesis Effects 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
231100000167 toxic agent Toxicity 0.000 description 3
239000003440 toxic substance Substances 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
241000701447 unidentified baculovirus Species 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
208000007089 vaccinia Diseases 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 description 2
MTVWFVDWRVYDOR-UHFFFAOYSA-N 3,4-Dihydroxyphenylglycol Chemical compound OCC(O)C1=CC=C(O)C(O)=C1 MTVWFVDWRVYDOR-UHFFFAOYSA-N 0.000 description 2
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
102000055025 Adenosine deaminases Human genes 0.000 description 2
238000008940 Alkaline Phosphatase assay kit Methods 0.000 description 2
206010061818 Disease progression Diseases 0.000 description 2
101710121417 Envelope glycoprotein Proteins 0.000 description 2
108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 description 2
108010035235 Phleomycins Proteins 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
108020005067 RNA Splice Sites Proteins 0.000 description 2
102100030398 Twist-related protein 1 Human genes 0.000 description 2
108010003533 Viral Envelope Proteins Proteins 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000002798 bone marrow cell Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000030833 cell death Effects 0.000 description 2
230000007910 cell fusion Effects 0.000 description 2
230000006037 cell lysis Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000001461 cytolytic effect Effects 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
238000009826 distribution Methods 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
229940011871 estrogen Drugs 0.000 description 2
239000000262 estrogen Substances 0.000 description 2
102000015694 estrogen receptors Human genes 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
230000004927 fusion Effects 0.000 description 2
238000001476 gene delivery Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
210000004602 germ cell Anatomy 0.000 description 2
239000003862 glucocorticoid Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
230000006028 immune-suppresssive effect Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000002743 insertional mutagenesis Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
229960000318 kanamycin Drugs 0.000 description 2
229930027917 kanamycin Natural products 0.000 description 2
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
229930182823 kanamycin A Natural products 0.000 description 2
230000021633 leukocyte mediated immunity Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
210000005229 liver cell Anatomy 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
230000011987 methylation Effects 0.000 description 2
238000007069 methylation reaction Methods 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
239000008267 milk Substances 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
229940127073 nucleoside analogue Drugs 0.000 description 2
150000003833 nucleoside derivatives Chemical class 0.000 description 2
231100000255 pathogenic effect Toxicity 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
108700004029 pol Genes Proteins 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
238000010839 reverse transcription Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
229940037128 systemic glucocorticoids Drugs 0.000 description 2
108700004027 tat Genes Proteins 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000011830 transgenic mouse model Methods 0.000 description 2
239000001226 triphosphate Substances 0.000 description 2
235000011178 triphosphate Nutrition 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
IPVFGAYTKQKGBM-BYPJNBLXSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 IPVFGAYTKQKGBM-BYPJNBLXSA-N 0.000 description 1
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 1
NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
GIMSJJHKKXRFGV-BYPJNBLXSA-N 4-amino-1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidin-2-one Chemical compound C1=C(I)C(N)=NC(=O)N1[C@H]1[C@@H](F)[C@H](O)[C@@H](CO)O1 GIMSJJHKKXRFGV-BYPJNBLXSA-N 0.000 description 1
PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241001073224 Baeopogon indicator Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
101150069832 CD2 gene Proteins 0.000 description 1
102000032165 CD4 receptor binding proteins Human genes 0.000 description 1
108091010591 CD4 receptor binding proteins Proteins 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
241000272194 Ciconiiformes Species 0.000 description 1
108091062157 Cis-regulatory element Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
108020004394 Complementary RNA Proteins 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
101150074155 DHFR gene Proteins 0.000 description 1
HOOWCUZPEFNHDT-UHFFFAOYSA-N DHPG Natural products OC(=O)C(N)C1=CC(O)=CC(O)=C1 HOOWCUZPEFNHDT-UHFFFAOYSA-N 0.000 description 1
102000052510 DNA-Binding Proteins Human genes 0.000 description 1
101710096438 DNA-binding protein Proteins 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
241000255925 Diptera Species 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
101150005585 E3 gene Proteins 0.000 description 1
102100038796 E3 ubiquitin-protein ligase TRIM13 Human genes 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
-1 FIAU triphosphates Chemical class 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108010093031 Galactosidases Proteins 0.000 description 1
102000002464 Galactosidases Human genes 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108700007698 Genetic Terminator Regions Proteins 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108010010369 HIV Protease Proteins 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
101000664589 Homo sapiens E3 ubiquitin-protein ligase TRIM13 Proteins 0.000 description 1
101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
108700002232 Immediate-Early Genes Proteins 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
101710203526 Integrase Proteins 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108010025815 Kanamycin Kinase Proteins 0.000 description 1
ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
108700005089 MHC Class I Genes Proteins 0.000 description 1
102100025169 Max-binding protein MNT Human genes 0.000 description 1
241000713869 Moloney murine leukemia virus Species 0.000 description 1
102000047918 Myelin Basic Human genes 0.000 description 1
101710107068 Myelin basic protein Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108010047620 Phytohemagglutinins Proteins 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
101150085390 RPM1 gene Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
101800002899 Soluble alkaline phosphatase Proteins 0.000 description 1
108010085012 Steroid Receptors Proteins 0.000 description 1
101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
241000030538 Thecla Species 0.000 description 1
102000007238 Transferrin Receptors Human genes 0.000 description 1
108010033576 Transferrin Receptors Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
206010058874 Viraemia Diseases 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108010087302 Viral Structural Proteins Proteins 0.000 description 1
230000010530 Virus Neutralization Effects 0.000 description 1
108010066342 Virus Receptors Proteins 0.000 description 1
102000018265 Virus Receptors Human genes 0.000 description 1
239000005862 Whey Substances 0.000 description 1
102000007544 Whey Proteins Human genes 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000009831 antigen interaction Effects 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
239000012911 assay medium Substances 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000034303 cell budding Effects 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
208000016350 chronic hepatitis B virus infection Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
230000030944 contact inhibition Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
238000013461 design Methods 0.000 description 1
230000010460 detection of virus Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
108700004026 gag Genes Proteins 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
102000034238 globular proteins Human genes 0.000 description 1
108091005896 globular proteins Proteins 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
102000055277 human IL2 Human genes 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008073 immune recognition Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
239000002523 lectin Substances 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000006371 metabolic abnormality Effects 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
201000008026 nephroblastoma Diseases 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000010397 one-hybrid screening Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000001885 phytohemagglutinin Effects 0.000 description 1
108010031345 placental alkaline phosphatase Proteins 0.000 description 1
101150088264 pol gene Proteins 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
230000007859 posttranscriptional regulation of gene expression Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000009117 preventive therapy Methods 0.000 description 1
238000009516 primary packaging Methods 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000027380 protein glycosylation in Golgi Effects 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
108010043277 recombinant soluble CD4 Proteins 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000009758 senescence Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
102000005969 steroid hormone receptors Human genes 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000010257 thawing Methods 0.000 description 1
102000004217 thyroid hormone receptors Human genes 0.000 description 1
108090000721 thyroid hormone receptors Proteins 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
108091006106 transcriptional activators Proteins 0.000 description 1
108091006107 transcriptional repressors Proteins 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
230000010415 tropism Effects 0.000 description 1
230000005909 tumor killing Effects 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
230000004572 zinc-binding Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Immunology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Oncology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Endocrinology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Emergency Medicine (AREA)

IL8970189A 1988-03-21 1989-03-21 Recombinant retroviruses method for the production thereof and pharmaceutical compositions containing the same IL89701A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US17051588A	1988-03-21	1988-03-21

Publications (2)

Publication Number	Publication Date
IL89701A0 IL89701A0 (en)	1989-09-28
IL89701A true IL89701A (en)	1995-07-31

Family

ID=22620165

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL8970189A IL89701A (en)	1988-03-21	1989-03-21	Recombinant retroviruses method for the production thereof and pharmaceutical compositions containing the same

Country Status (16)

Country	Link
EP (2)	EP0334301B1 (fr)
JP (5)	JPH03504079A (fr)
CN (1)	CN1038306A (fr)
AT (2)	ATE174960T1 (fr)
AU (1)	AU651311B2 (fr)
CA (1)	CA1341585C (fr)
CH (1)	CH684094A5 (fr)
DE (2)	DE68929122T2 (fr)
DK (1)	DK175857B1 (fr)
ES (1)	ES2139810T3 (fr)
FI (1)	FI113476B (fr)
GB (2)	GB2236753B (fr)
GR (1)	GR3032940T3 (fr)
IL (1)	IL89701A (fr)
NO (1)	NO314596B1 (fr)
WO (1)	WO1989009271A1 (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5997859A (en) *	1988-03-21	1999-12-07	Chiron Corporation	Method for treating a metastatic carcinoma using a conditionally lethal gene
US5716826A (en) *	1988-03-21	1998-02-10	Chiron Viagene, Inc.	Recombinant retroviruses
US6569679B1 (en)	1988-03-21	2003-05-27	Chiron Corporation	Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
US5591624A (en) *	1988-03-21	1997-01-07	Chiron Viagene, Inc.	Retroviral packaging cell lines
US5662896A (en) *	1988-03-21	1997-09-02	Chiron Viagene, Inc.	Compositions and methods for cancer immunotherapy
US6133029A (en)	1988-03-21	2000-10-17	Chiron Corporation	Replication defective viral vectors for infecting human cells
US5747324A (en) *	1988-06-10	1998-05-05	Therion Biologics Corporation	Self-assembled, defective, non-self-propagating lentivirus particles
US5614404A (en) *	1988-06-10	1997-03-25	Theriod Biologics, Incorporated	Self-assembled, defective, non-self-propagating lentivirus particles
US5650148A (en) *	1988-12-15	1997-07-22	The Regents Of The University Of California	Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
DE69033975T2 (de) *	1989-01-23	2002-10-02	Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville	Rekombinanttherapien für Infektionen und hyperproliferative Störungen
WO1990007936A1 (fr) *	1989-01-23	1990-07-26	Chiron Corporation	Therapies de recombinaison pour infections et troubles hyperproliferatifs
JP3140757B2 (ja) *	1989-02-06	2001-03-05	デイナ・フアーバー・キヤンサー・インステイテユート	パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
US6673776B1 (en)	1989-03-21	2004-01-06	Vical Incorporated	Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5693622A (en) *	1989-03-21	1997-12-02	Vical Incorporated	Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
JPH04504361A (ja) *	1989-04-05	1992-08-06	ノバセル　コーポレイション	感染性標的化複製―欠陥ビリオン
AU648261B2 (en) *	1989-08-18	1994-04-21	Novartis Vaccines And Diagnostics, Inc.	Recombinant retroviruses delivering vector constructs to target cells
US6337209B1 (en)	1992-02-26	2002-01-08	Glaxo Wellcome Inc.	Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB8919607D0 (en) *	1989-08-30	1989-10-11	Wellcome Found	Novel entities for cancer therapy
JP3203599B2 (ja) *	1989-10-24	2001-08-27	カイロンコーポレイション	感染性タンパク質デリバリーシステム
FR2655855B1 (fr) *	1989-12-20	1992-04-10	Pasteur Institut	Protection genetique d'animaux contre l'infection par le virus leucemogene bovin, et provirus et virus recombinant derive de ce virus.
US6706694B1 (en)	1990-03-21	2004-03-16	Vical Incorporated	Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en)	1991-11-12	2001-05-08	Vical Incorporated	Stimulating vascular growth by administration of DNA sequences encoding VEGF
US6555108B1 (en) *	1990-09-14	2003-04-29	The General Hospital Corporation	Implanting HSV-TK retrovirus producing cells to treat tumors
US6537541B1 (en) *	1990-09-14	2003-03-25	The General Hospital Corporation	Implantation of HSV-TK retrovirus producer cells to destroy glioma
EP0854193A1 (fr) *	1990-09-21	1998-07-22	Chiron Corporation	Lignée cellulaire humaine pour l'empaquetage des Rétrovirus
US7374768B1 (en)	1990-09-25	2008-05-20	Xenova Research Limited	Viral vaccines
DE69132311T2 (de)	1990-09-25	2000-12-14	Cantab Pharmaceuticals Research Ltd., Cambridge	Bei einer transkomplementenden zellinie erzeugter defektiver virenimpfstoff
US5665362A (en) *	1990-09-25	1997-09-09	Cantab Pharmaceuticals Research Limited	Viral vaccines
US5837261A (en) *	1990-09-25	1998-11-17	Cantab Pharmaceuticals Research Limited	Viral vaccines
GB9100612D0 (en) *	1991-01-11	1991-02-27	Univ Edinburgh	Method of altering the metabolic state of non-dividing cells,transgenic animals and therapeutic agents
GB9104165D0 (en) *	1991-02-27	1991-04-17	Wellcome Found	Novel entities for hiv therapy
GB9107631D0 (en) *	1991-04-10	1991-05-29	British Bio Technology	Proteinaceous particles
WO1993000103A1 (fr) *	1991-06-21	1993-01-07	The Wistar Institute Of Anatomy And Biology	Proteines d'enveloppe chimeriques pour le ciblage de virus
AU2512792A (en) *	1991-08-30	1993-04-05	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	Defective interfering hiv particles with chimeric cd4-env
EP0564645B1 (fr) *	1991-10-30	1999-12-29	Universite Pierre Et Marie Curie Paris Vi	Cellules transformees pour la prevention ou le traitement de maladies induites par des virus, notamment retrovirus pathogenes
WO1993010218A1 (fr)	1991-11-14	1993-05-27	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Vecteurs comprenant des genes etrangers et des marqueurs selectifs negatifs
US7223411B1 (en)	1992-07-31	2007-05-29	Dana-Farber Cancer Institute	Herpesvirus replication defective mutants
GB2269175A (en) *	1992-07-31	1994-02-02	Imperial College	Retroviral vectors
DE69333471T2 (de) *	1992-11-09	2005-02-24	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Erzielbare vektorenpartikel
WO1994016072A1 (fr) *	1993-01-14	1994-07-21	Intracell Therapeutics, Inc.	Vecteurs permettant de reguler la replication de vih-1 et procedes d'utilisation
WO1995014091A2 (fr) *	1993-11-18	1995-05-26	Chiron Viagene, Inc.	Compositions et procedes d'utilisation de genes a pouvoir letal conditionnel
US6451571B1 (en)	1994-05-02	2002-09-17	University Of Washington	Thymidine kinase mutants
AU2434195A (en) *	1994-05-02	1995-11-29	University Of Washington	Thymidine kinase mutants
US5888814A (en) *	1994-06-06	1999-03-30	Chiron Corporation	Recombinant host cells encoding TNF proteins
WO1995033842A1 (fr) *	1994-06-07	1995-12-14	Immunomedics, Inc.	Vecteurs retroviraux sans danger, leur production et utilisation
GB9414652D0 (en) *	1994-07-20	1994-09-07	Moeller Erna	Method of treatment
WO1997015679A1 (fr) *	1995-10-27	1997-05-01	The Trustees Of The University Of Pennsylvania	Virus recombines contenant des elements genetiques mobiles et procedes d'utilisation desdits virus en therapie genique
FR2741358B1 (fr) *	1995-11-17	1998-01-02	Centre Nat Rech Scient	Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn
US6365344B1 (en)	1996-01-23	2002-04-02	The Board Of Trustees Of The Leland Stanford Junior University	Methods for screening for transdominant effector peptides and RNA molecules
DK0877752T3 (da)	1996-01-23	2003-09-15	Univ Leland Stanford Junior	Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler
US6776986B1 (en)	1996-06-06	2004-08-17	Novartis Ag	Inhibition of HIV-1 replication by antisense RNA expression
ATE359372T1 (de) *	1996-07-22	2007-05-15	Us Gov Health & Human Serv	Vektoren zur inhibierung von viralem und tumorwachstum
US6953687B1 (en)	1997-07-17	2005-10-11	The United States Of America As Represented By The Department Of Health And Human Services	Vectors for delivering viral and oncogenic inhibitors
US6544523B1 (en)	1996-11-13	2003-04-08	Chiron Corporation	Mutant forms of Fas ligand and uses thereof
GB9703802D0 (en) *	1997-02-24	1997-04-16	Kingsman Susan M	Anti-hiv peptides and proteins
WO1998044938A1 (fr)	1997-04-10	1998-10-15	University Of Southern California	Proteines modifiees se fixant a des composants de matrice extracellulaires
GB9711578D0 (en) *	1997-06-04	1997-07-30	Oxford Biomedica Ltd	Novel retroviral vector production systems
DE19737442C2 (de) *	1997-08-22	1999-06-24	Olfert Landt Tib Molbiol Synth	Proteinumhüllte Polyribonukleinsäuren, ein Verfahren zu ihrer Herstellung und ihre Verwendung
WO1999011292A2 (fr) *	1997-09-02	1999-03-11	Chiron Corporation	Compositions et methodes de traitement de l'arthrite par therapie genique
US6914131B1 (en)	1998-10-09	2005-07-05	Chiron S.R.L.	Neisserial antigens
CA2671261A1 (fr)	1997-11-06	1999-05-20	Novartis Vaccines And Diagnostics S.R.L.	Antigenes de neisseria
EP1047784B2 (fr)	1998-01-14	2015-03-18	Novartis Vaccines and Diagnostics S.r.l.	Antigenes du neisseria meningitidis
US7078483B2 (en)	1998-04-29	2006-07-18	University Of Southern California	Retroviral vectors including modified envelope escort proteins
EP2261338A3 (fr)	1998-05-01	2012-01-04	Novartis Vaccines and Diagnostics, Inc.	Antigènes de Neisseria meningitidis et compositions
WO2000006760A1 (fr) *	1998-07-29	2000-02-10	The Government Of The United States Of America, R Epresented By The Secretary, Department Of Health And Human Services	Utilisation d'elements de transport constitutifs pour le control de la gamme d'hote
US6399354B1 (en)	1998-07-31	2002-06-04	President And Fellows Of Harvard College	Replication-competent virus expressing a detectable fusion protein
AU2221600A (en)	1998-12-31	2000-07-31	Chiron Corporation	Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en)	1998-12-31	2011-05-03	Novartis Vaccines & Diagnostics, Inc	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2000066741A2 (fr)	1999-04-30	2000-11-09	Chiron S.P.A.	Antigenes de neisseria conserves
GB9911683D0 (en)	1999-05-19	1999-07-21	Chiron Spa	Antigenic peptides
GB9916529D0 (en)	1999-07-14	1999-09-15	Chiron Spa	Antigenic peptides
DE69941703D1 (de) *	1999-10-11	2010-01-07	Pasteur Institut	Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
JP2004508801A (ja)	1999-10-29	2004-03-25	カイロン　ソチエタ　ア　レスポンサビリタ　リミタータ	ナイセリア抗原性ペプチド
PT2289545T (pt)	2000-01-17	2016-09-06	Glaxosmithkline Biologicals Sa	Vacina de omv suplementada contra meningococos
NZ521531A (en)	2000-02-28	2005-12-23	Chiron S	Heterologous expression of neisserial proteins
CA2881568C (fr)	2000-10-27	2019-09-24	Novartis Vaccines And Diagnostics, Inc.	Acides nucleiques et proteines derives des groupes de streptocoques a et b
AU2002235141A1 (en)	2000-11-27	2002-06-03	Geron Corporation	Glycosyltransferase vectors for treating cancer
AU2002236517A1 (en)	2000-11-29	2002-06-11	University Of Southern California	Targetet retoviral vectors for cancer immunotherapy
FR2820146B1 (fr) *	2001-01-29	2003-06-27	Centre Nat Rech Scient	Procede d'obtention de cellules d'encapsidation fortement productrices de retrovirus par elimination, au sein de la culture, des cellules permissives a l'infection par le retro virus produit
GB0107661D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Staphylococcus aureus
GB0107658D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Streptococcus pneumoniae
GB0111442D0 (en) *	2001-05-10	2001-07-04	Isis Innovation	Method for preparing recombinant virus
EP2280074A3 (fr)	2001-07-05	2011-06-22	Novartis Vaccines and Diagnostics, Inc.	Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
EP1411770A4 (fr)	2001-07-05	2006-05-10	Chiron Corp	Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
RU2331435C2 (ru)	2001-12-12	2008-08-20	Чирон Срл.	Иммунизация против chlamydia trachomatis
GB0308198D0 (en)	2003-04-09	2003-05-14	Chiron Srl	ADP-ribosylating bacterial toxin
EP2353389B1 (fr)	2003-04-21	2015-11-04	Epeius Biotechnologies Corporation	Compositions permettant de traiter les troubles
US20070178066A1 (en)	2003-04-21	2007-08-02	Hall Frederick L	Pathotropic targeted gene delivery system for cancer and other disorders
JP4792390B2 (ja)	2004-03-29	2011-10-12	株式会社ガルファーマ	新規ガレクチン９改変体タンパク質及びその用途
GB0606190D0 (en)	2006-03-28	2006-05-10	Isis Innovation	Construct
PT2054431E (pt)	2006-06-09	2011-11-03	Novartis Ag	Confórmeros de adesinas bacterianas
CN107022217A (zh) *	2017-06-08	2017-08-08	南通市乐佳涂料有限公司	一种采用水包水的环保抗锈涂料
CN109722465B (zh) *	2019-01-07	2022-02-01	福建省疾病预防控制中心(福建省健康教育促进中心、福建省卫生检验检测中心)	一种hiv耐药检测载体和构建方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2559159B1 (fr) *	1984-02-02	1986-09-12	Inst Nat Sante Rech Med	Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues
CA1310924C (fr) *	1986-04-24	1992-12-01	Francis P. Mccormick	Systeme d'administration d'un medicament a l'aide de particules infectieuses
FR2606030B1 (fr) *	1986-10-31	1989-10-20	Pasteur Institut	Retrovirus recombinant defectif, son procede de fabrication et ses applications, notamment pour l'etude de l'interaction des retrovirus sauvages avec des lignees cellulaires infectables par celui-ci
AU647013B2 (en) *	1988-08-22	1994-03-17	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Retroviral vectors expressing soluble CD4: a gene therapy for aids

1989
- 1989-03-20 WO PCT/US1989/001139 patent/WO1989009271A1/fr not_active Ceased
- 1989-03-20 JP JP1503903A patent/JPH03504079A/ja not_active Withdrawn
- 1989-03-20 CN CN89102697A patent/CN1038306A/zh active Pending
- 1989-03-20 CH CH4290/89A patent/CH684094A5/de not_active IP Right Cessation
- 1989-03-20 AU AU33640/89A patent/AU651311B2/en not_active Expired
- 1989-03-21 IL IL8970189A patent/IL89701A/en unknown
- 1989-03-21 EP EP89105059A patent/EP0334301B1/fr not_active Expired - Lifetime
- 1989-03-21 AT AT89105059T patent/ATE174960T1/de not_active IP Right Cessation
- 1989-03-21 DE DE68929122T patent/DE68929122T2/de not_active Revoked
- 1989-03-21 DE DE68928884T patent/DE68928884T2/de not_active Expired - Fee Related
- 1989-03-21 CA CA005943744A patent/CA1341585C/fr not_active Expired - Fee Related
- 1989-03-21 EP EP95115441A patent/EP0702084B1/fr not_active Revoked
- 1989-03-21 ES ES95115441T patent/ES2139810T3/es not_active Expired - Lifetime
- 1989-03-21 AT AT95115441T patent/ATE187983T1/de not_active IP Right Cessation
1990
- 1990-09-20 FI FI904647A patent/FI113476B/fi not_active IP Right Cessation
- 1990-09-20 GB GB9020586A patent/GB2236753B/en not_active Expired - Lifetime
- 1990-09-20 DK DK199002268A patent/DK175857B1/da not_active IP Right Cessation
- 1990-09-20 NO NO19904103A patent/NO314596B1/no not_active IP Right Cessation
1992
- 1992-08-10 GB GB9217086A patent/GB2255777B/en not_active Expired - Fee Related
1998
- 1998-12-24 JP JP10368260A patent/JPH11262397A/ja not_active Withdrawn
2000
- 2000-03-10 GR GR20000400636T patent/GR3032940T3/el not_active IP Right Cessation
2002
- 2002-03-11 JP JP2002066181A patent/JP2002306188A/ja not_active Withdrawn
2003
- 2003-10-10 JP JP2003353011A patent/JP2004008227A/ja active Pending
2007
- 2007-08-01 JP JP2007200751A patent/JP2007289206A/ja active Pending

Also Published As

Publication number	Publication date
GB2236753A (en)	1991-04-17
DK175857B1 (da)	2005-04-11
AU3364089A (en)	1989-10-16
IL89701A0 (en)	1989-09-28
CA1341585C (fr)	2008-11-18
GR3032940T3 (en)	2000-07-31
EP0334301B1 (fr)	1998-12-23
ES2139810T3 (es)	2000-02-16
GB9020586D0 (en)	1991-01-23
ATE187983T1 (de)	2000-01-15
CH684094A5 (de)	1994-07-15
JP2002306188A (ja)	2002-10-22
DE68929122D1 (de)	2000-01-27
JP2004008227A (ja)	2004-01-15
GB2255777B (en)	1993-02-03
DK226890D0 (da)	1990-09-20
WO1989009271A1 (fr)	1989-10-05
GB2236753B (en)	1993-02-03
DE68928884T2 (de)	1999-05-12
GB9217086D0 (en)	1992-09-23
FI113476B (fi)	2004-04-30
GB2255777A (en)	1992-11-18
NO314596B1 (no)	2003-04-14
JPH03504079A (ja)	1991-09-12
FI904647A0 (fi)	1990-09-20
JP2007289206A (ja)	2007-11-08
DE68929122T2 (de)	2000-04-20
ATE174960T1 (de)	1999-01-15
DE68928884D1 (de)	1999-02-04
EP0334301A1 (fr)	1989-09-27
CN1038306A (zh)	1989-12-27
NO904103D0 (no)	1990-09-20
JPH11262397A (ja)	1999-09-28
EP0702084B1 (fr)	1999-12-22
NO904103L (no)	1990-11-16
AU651311B2 (en)	1994-07-21
EP0702084A1 (fr)	1996-03-20
DK226890A (da)	1990-11-20

Legal Events

Date	Code	Title
1996-06-18	KB	Patent renewed
1999-09-22	KB	Patent renewed
2003-06-24	KB	Patent renewed

Publication	Publication Date	Title
CA1341585C (fr)	2008-11-18	Retrovirus recombines
US6495349B1 (en)	2002-12-17	Chimeric gene constructs
CA2066053C (fr)	2001-12-11	Retrovirus recombinants livrant des constructeurs de vecteur aux cellules cibles
US5856185A (en)	1999-01-05	Method for making reflection defective retroviral vectors for infecting human cells
US5997859A (en)	1999-12-07	Method for treating a metastatic carcinoma using a conditionally lethal gene
CA2158936C (fr)	2012-02-21	Compositions et procedes d'utilisation de genes a pouvoir letal conditionnel
JPH11505128A (ja)	1999-05-18	キメラインテグラーゼタンパク質に媒介される真核生物ゲノム中へのベクター構築物の位置特異的組み込み
AU689799B2 (en)	1998-04-09	Recombinant retroviruses
US6569679B1 (en)	2003-05-27	Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
GB2254424A (en)	1992-10-07	Indicator cells and retroviruses for the detection of gene sequenes
Li	1995	Use of retroviral vectors in studying gag-specific CTL in cats infected with feline immunodeficiency virus